Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07363473

JOURNEY LVAD: JOURNEY Left Ventricular Assist Device

The objective of this study is to assess the safety and effectiveness of the J-Valve Transfemoral Transcatheter Heart Valve System in patients on left ventricular assist device (LVAD) support with significant native aortic valve regurgitation (AR).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult with durable left ventricular assist device (LVAD) support and clinically significant AR (grade 4 or higher as assessed by core lab using TTE and adjunct TEE, if necessary) leading to LVAD dysfunction
  • Symptomatic according to New York Heart Association (NYHA) functional class II or higher
  • High risk for surgery as judged by a multi-disciplinary heart team
  • Suitable anatomy to accommodate the insertion, delivery, and deployment of the study devices (see anatomic exclusions below)
  • Written informed consent and agreement to comply with all required follow-up visits at investigational site

Exclusion criteria

  • Prior aortic valve replacement or repair
  • Aortic valve stenosis > moderate as assessed by core lab
  • Severe mitral valve or tricuspid valve regurgitation as assessed by core lab
  • Severe mitral valve or tricuspid valve stenosis as assessed by core lab
  • Active infection requiring current antibiotic therapy, including infective endocarditis
  • Cardiac imaging evidence of cardiac mass, thrombus or vegetation
  • Inability to tolerate or a condition precluding treatment with antithrombotic (antiplatelet, anticoagulant) therapy
  • Renal insufficiency (eGFR <25 mL/min/1.73m2) or end stage renal disease requiring chronic dialysis
  • Cirrhosis (Child-Pugh Class B or C)
  • Leukopenia (WBC <3000 cells/mcL), thrombocytopenia (platelet count <50,000 cells/mcL), anemia (hemoglobin <9 g/dL), history of bleeding diathesis, coagulopathy, or hypercoagulable state (unless therapeutically stable)
  • Known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, clopidogrel, Nitinol (Nickel, Titanium) or sensitivity to contrast media which cannot be adequately premedicated
  • Clinically significant untreated coronary artery disease requiring revascularization or anticipated coronary revascularization procedure within 12 months post-index procedure
  • Acute myocardial infarction within 30 days prior to index procedure
  • PCI within 30 days prior to index procedure
  • Carotid intervention within 6 weeks prior to index procedure or carotid artery disease requiring intervention
  • Previous, or planned, other surgical or interventional procedures within 30 days before, during, or within 30 days after the index procedure
  • Uncontrolled atrial fibrillation
  • Severe right ventricular (RV) dysfunction or chronic inotrope support (>30 days)
  • Severe pulmonary hypertension (systolic pulmonary artery pressure >80 mmHg measured by right heart catheterization)
  • Severe chronic obstructive pulmonary disease (COPD) requiring chronic oral steroids or requiring continuous home oxygen
  • Stroke (cerebrovascular accident, CVA), transient ischemic attack (TIA) or neurological signs and symptoms attributed to carotid or vertebrobasilar disease within 90 days prior to index procedure
  • Estimated life expectancy of less than 12 months
  • Pregnancy or intent to become pregnant prior to completion of all protocol follow-up requirements
  • Participation in another investigational study that has not reached its primary endpoint
  • Considered to be part of a vulnerable population

Anatomic Exclusions:

  • Ascending aortic diameter ≥5.5 cm as assessed by core lab
  • Aortic annulus perimeter <57 mm or >104 mm as assessed by core lab
  • Inappropriate anatomy for femoral introduction and delivery of the study system
  • Congenital aortic valve disease including unicuspid, bicuspid, or quadricuspid aortic valve anatomy as assessed by core lab
  • Congenital univentricle or other condition that, in the opinion of the investigator and/or consulting physician, may constitute an unwarranted surgical risk
  • Excessive aortic valve prolapse or leaflet deterioration that would preclude proper seating of the implant in the aortic annulus
  • Abdominal/thoracic aortic aneurysm ≥5.0 cm as assessed by core lab
  • Aorto-iliac disease requiring intervention to facilitate delivery of access sheath
  • Excessive tortuosity of delivery system pathway, defined as severe tortuosity of multiple vessels including iliofemoral, thoracoabdominal aorta, aortic arch, and/or LV-aortic root angle >80°

Treatment and study plan

J-Valve Transfemoral System

Device

Treatment includes using the J-Valve Transfemoral (TF) System, a transcatheter aortic valve replacement system that consists of the J-Valve TF Bioprosthesis and the J-Valve TF Delivery Device and Loading Accessories, during transcatheter aortic valve replacement (TAVR). The Edwards 16Fr eSheath+ Introducer Set may be used for the introduction and removal of the J-Valve TF System.

Primary outcomes

  1. Primary Effectiveness Endpoint

    Time frame: 30 days

    Freedom from moderate or severe total aortic regurgitation

  2. Primary Safety Endpoint

    Time frame: 30 days

    Freedom from all-cause mortality

Secondary outcomes

  1. Valve embolization

    Time frame: During index procedure

    Valve embolization

  2. Need for second bioprosthetic valve

    Time frame: During index procedure

    Need for second bioprosthetic valve

  3. Change in cardiovascular-specific health status

    Time frame: 30 days compared with baseline

    Change in cardiovascular-specific health status as measured by the Kansas City Cardiomyopathy Questionnaire overall summary (KCCQ-OS) score

Study contacts

Contact information is provided by the study sponsor or research team.

Sheri L Halverson, MPH

CONTACT

[email protected]

1-800-424-3278

Sponsors and collaborators

Lead sponsor

JC Medical, Inc., an affiliate of Edwards Lifesciences LLC

Industry

Registry information

Official study title

Transcatheter Therapy to Treat Aortic Regurgitation in the Presence of a Left Ventricular Assist Device

Important dates

Study start
2026
Primary completion
2027
Study completion
2029
First posted
Jan 23, 2026
Registry last updated
Mar 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.